La chaîne d'options affiche les données clés des options sur actions de CytomX Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour CytomX Therapeutics..

CytomX Therapeutics (NASDAQ:CTMX) Stock, Chaîne d'Options

CYTOMX THERAPEUTICS INC

CytomX Therapeutics

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- New York Mortgage Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYMT#NASDAQ">NYMT</a>) (the "Company") today announced that it has acquired the remaining 50% ownership interest in Constructive Loans, LLC ("Constructive"), a leading originator in business purpose loans for residential real estate investors. This all-cash transaction, completed through a wholly owned subsidiary of the Company, represents a significant milestone in the Company's ongoing strategy to diversify and scale its recurring earnings through the inclusion of a top operating platform.
This acquisition builds on the Company's initial strategic investment in Constructive in 2021 and reflects the Company's belief in Constructive's growth potential and value to the residential credit market. This transaction will bolster the Company's access to Constructive's proprietary origination channels and broad third-party distribution network.
Constructive has demonstrated solid profitability and performance since its founding in 2017. Over the last twelve months ended June 30, 2025, Constructive has originated more than $1.7 billion of business purpose loans. Constructive will operate as an independent subsidiary of the Company with its experienced leadership team remaining in place.
"We are excited to take the next steps in our partnership with the talented team at Constructive. We believe that the acquisition of Constructive represents a step forward towards raising and diversifying the Company's recurring income," said Jason Serrano, CEO of the Company. "This transaction appreciably expands NYMT's presence within the residential credit markets and supports our core strategy of investing in business purpose loans."
Nicholas Mah, President of the Company, added: "We are pleased to welcome the Constructive team to NYMT. Constructive has demonstrated an ability to maintain solid loan performance while expanding origination volume, and we believe that Constructive is well positioned to meet the growing financing needs of the single-family investor community. With a shared philosophy of strong credit underwriting, we are excited to build on this success."
"Since our founding, Constructive has provided reliable and competitive capital to residential real estate investors," said Ben Fertig, President of Constructive, "We are thrilled to join NYMT with their residential mortgage credit expertise and deep capital market presence. We are excited to work together to bring the next level of growth in our origination of high-quality business purpose loans, and to further elevate the value we can deliver to Constructive's clients."
BTIG, LLC served as exclusive financial advisor. Mayer Brown LLP served as&nbsp;M&amp;A counsel, and Vinson &amp; Elkins LLP acted as tax and employment counsel to the Company in connection with the transaction.

News

General

NYMT

New York Mortgage Trust Acquires The Remaining 50% Ownership Interest in Constructive Loan, LLC

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 4.54% on an annualized basis producing an average annual return of 16.99%. Currently, Verisk Analytics has a market capitalization of $41.98 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $1,042.15 today based on a price of $300.14 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752614117_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VRSK

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Silvercorp Metals Expects Q1 2026 Revenue Of ~$81.3M, Up 13% YoY; Expects Silver Production Of 1.8M Ounces, Up 6% YoY

<h3>Gainers</h3>
<ul>
<li>Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) shares moved upwards by 10.3% to $0.61 during Tuesday's after-market session. The company's market cap stands at $9.0 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares rose 6.72% to $0.13. The market value of their outstanding shares is at $8.3 million. </li>
<li>YSX Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) stock increased by 4.88% to $5.8. The market value of their outstanding shares is at $118.1 million. </li>
<li>Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) stock moved upwards by 4.59% to $0.42. The company's market cap stands at $79.3 million. </li>
<li>Lottery.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEGG#NASDAQ">SEGG</a>) stock rose 4.23% to $1.23. The market value of their outstanding shares is at $32.3 million. </li>
<li>Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) stock moved upwards by 3.88% to $2.14. The market value of their outstanding shares is at $60.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Neo-Concept International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) shares fell 4.9% to $2.12 during Tuesday's after-market session. The market value of their outstanding shares is at $8.3 million. </li>
<li>Volcon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) shares decreased by 4.9% to $7.58. The company's market cap stands at $4.2 million. </li>
<li>Epsium Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) shares declined by 4.14% to $23.2. The company's market cap stands at $283.9 million. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) shares declined by 4.05% to $3.05. The market value of their outstanding shares is at $21.3 million. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) shares decreased by 3.6% to $0.48. The market value of their outstanding shares is at $5.4 million. </li>
<li>Allied Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGAE#NASDAQ">AGAE</a>) stock decreased by 3.13% to $1.5. The company's market cap stands at $62.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AGAE

ALUR

EPSM

LESL

NAAS

SEGG

SPHL

VLCN

YSXT

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock rose 29.1% to $8.9 during Tuesday's after-market session. The market value of their outstanding shares is at $34.1 million. </li>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock increased by 18.18% to $1.69. The market value of their outstanding shares is at $67.3 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares rose 8.84% to $10.58. The market value of their outstanding shares is at $54.2 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares rose 8.44% to $1.67. The market value of their outstanding shares is at $138.8 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares moved upwards by 6.74% to $22.0. The company's market cap stands at $312.0 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock moved upwards by 6.43% to $1.82. The market value of their outstanding shares is at $21.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares declined by 23.8% to $9.4 during Tuesday's after-market session. The market value of their outstanding shares is at $5.2 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares fell 14.71% to $1.45. The market value of their outstanding shares is at $54.9 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares fell 9.41% to $1.06. The company's market cap stands at $11.5 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock decreased by 6.44% to $0.29. The market value of their outstanding shares is at $45.8 million. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) shares declined by 6.34% to $1.33. The company's market cap stands at $66.1 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares declined by 6.06% to $2.33. The company's market cap stands at $53.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

CELU

CTOR

CYCC

GANX

IKNA

KAPA

NUWE

PTHL

RBOT

RPTX

SCNX

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares increased by 62.6% to $0.12 during Tuesday's after-market session. The company's market cap stands at $10.3 million. </li>
<li>MingZhu Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) stock rose 7.15% to $0.76. The company's market cap stands at $56.7 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) shares moved upwards by 5.51% to $0.2. The company's market cap stands at $28.4 million. </li>
<li>Knightscope (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) stock rose 4.95% to $7.83. The company's market cap stands at $55.2 million. </li>
<li>ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) shares moved upwards by 4.57% to $0.55. The company's market cap stands at $27.7 million. </li>
<li>TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) stock increased by 4.52% to $0.77. The company's market cap stands at $37.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Skyline Builders Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKBL#NASDAQ">SKBL</a>) stock declined by 6.3% to $1.65 during Tuesday's after-market session. The market value of their outstanding shares is at $45.0 million. </li>
<li>JFB Construction (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFB#NASDAQ">JFB</a>) stock decreased by 4.26% to $7.67. The company's market cap stands at $79.2 million. </li>
<li>Concorde Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGL#NASDAQ">CIGL</a>) shares decreased by 3.7% to $3.65. The market value of their outstanding shares is at $77.9 million. </li>
<li>Webus International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>) stock declined by 3.39% to $2.0. The market value of their outstanding shares is at $45.5 million. </li>
<li>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) shares fell 3.32% to $0.7. The company's market cap stands at $23.2 million. </li>
<li>Erayak Power Solution Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAYA#NASDAQ">RAYA</a>) stock declined by 3.26% to $2.97. The company's market cap stands at $112.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CIGL

CLIR

KSCP

RAYA

SCWO

SKBL

TPIC

WETO

YGMZ

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) shares rose 25.7% to $4.25 during Tuesday's after-market session. The market value of their outstanding shares is at $24.4 million. </li>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) shares rose 16.31% to $46.48. The market value of their outstanding shares is at $2.1 billion. </li>
<li>Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) shares rose 5.59% to $1.51. The company's market cap stands at $183.8 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) stock moved upwards by 5.58% to $0.73. The market value of their outstanding shares is at $12.9 million. </li>
<li>BTC Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) shares increased by 5.09% to $3.3. The company's market cap stands at $20.5 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares moved upwards by 4.99% to $0.82. The market value of their outstanding shares is at $42.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>PicoCELA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) shares fell 19.6% to $0.65 during Tuesday's after-market session. The market value of their outstanding shares is at $112.9 million. </li>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) stock fell 6.09% to $2.16. The company's market cap stands at $26.2 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) shares fell 5.77% to $2.29. The company's market cap stands at $7.6 million. </li>
<li>TROOPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROO#NASDAQ">TROO</a>) stock decreased by 4.84% to $0.89. The market value of their outstanding shares is at $136.1 million. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) stock fell 4.79% to $4.18. The market value of their outstanding shares is at $7.1 million. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares declined by 4.2% to $4.09. The market value of their outstanding shares is at $6.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMNR

BTCT

DTST

LWLG

MOBX

OBLG

PCLA

SAGT

SOBR

SONM

TROO

12 Information Technology Stocks Moving In Tuesday's After-Market Session

Coffee giant Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) is amending its return-to-work policy for corporate employees, which could create a significant conflict of interest given the treatment afforded to new CEO Brian Niccol.
What Happened: As Starbucks seeks to complete a turnaround from declining sales, the company is focusing on employees working together in stores and offices worldwide.
Niccol outlined the company's new policy this week that will require corporate employees and managers to work in-person four days a week, Monday through Thursday. The policy upgrades and existing three-day in-person work requirement.
"To give partners time to adjust, this expectation will begin with the new fiscal year," Niccol said in a message to employees.
Corporate employees and managers will be required to work in Starbucks&#8217; corporate offices in Seattle and Toronto, or regional hubs across North America, starting in January 2026, <a href="https://nypost.com/2025/07/14/business/starbucks-orders-4-day-office-return-as-ceo-brian-niccol-keeps-remote-work-perk/">reported</a> the New York Post. The new policy also requires all managers at corporate locations to relocate to Seattle, Toronto, or other cities with regional offices within the next 12 months.
"We'll share more details before October, including our plans to ensure everyone has an assigned dedicated desk."
The four-day in-person work requirement is part of the company's "Back to Starbucks" turnaround strategy launched by Niccol.
"We are establishing our in-office culture because we do our best work when we're together. We share ideas more effectively, creatively solve hard problems, and move much faster."
The company will offer one-time exit packages to employees who refuse to comply with the new policy.
"If you decide you want to leave Starbucks for any reason, we respect that."
Niccol said the new policy is "the right path for Starbucks."
Read Also:<a href="https://www.benzinga.com/markets/asset-sales/25/07/46315542/starbucks-attracts-10-billion-in-bids-for-china-unit-amid-rising-competition"> Starbucks Attracts $10 Billion In Bids For China Unit Amid Rising Competition</a>
Why It's Important: As the new policy is announced, questions remain on where Niccol completes his daily work and how much of his time he spends working in-person versus remotely.
Niccol, who <a href="https://www.benzinga.com/news/24/08/40347476/ceo-switch-wipes-7b-off-chipotles-market-cap-adds-15b-to-starbucks">was hired away </a>from Chipotle Mexican Grill in 2024, has a main residence in Newport Beach, California.
At the time of his hiring, it was reported that Niccol would be permitted to continue residing in Newport Beach.
Starbucks said Niccol's "default" is residing in Seattle when he isn't traveling. The company declined to comment on Niccol working from California when asked by the New York Post.
The company previously said that Niccol would spend the majority of his time in Seattle or visiting stores and offices globally.
"His schedule will exceed the hybrid work guidelines and workplace expectations we have for all partners," a company spokesperson previously said.
With the hybrid work guidelines now meaning four days in the office and one at home, it remains unclear if Niccol is still exceeding those requirements.
Niccol received a favorable compensation package for joining the coffee giant, with reports saying he made $96 million in his first four months with the company from wages, a sign-on bonus and stock awards.
The annual compensation of $113 million makes Niccol one of the highest-paid CEOs in the country.
The Starbucks CEO also has a remote office near his home and a corporate jet at his disposal, along with other perks.
Starbucks has been in the middle of a turnaround as it faces declining sales, labor challenges from unions, increased competition, and concerns over higher inflation.
The coffee chain will likely be asked about Niccol's work locations in the coming months and could face increased employee pushback without clarity, or if it is true that the CEO is exempt from following the new policy.
SBUX Price Action: Starbucks stock trades at $92.48 on Tuesday versus a 52-week trading range of $71.55 to $117.46. The stock is up 0.3% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40343728/starbucks-analysts-mixed-on-new-ceo-brian-niccol-who-led-cmg-stock-650-higher-in-6-">Starbucks Analysts Mixed On New CEO Brian Niccol, Who Led CMG Stock 650% Higher In 6 Years: &#8216;Starbucks Is No Chipotle&#8217;</a></li>
</ul>
Photo: Shutterstock

Restaurants

Management

SBUX

Starbucks Return To Work Conflict Of Interest: Employees Told Four Days In Office As CEO Works From Home

Offerings

TECX

Tectonic Therapeutic Files For Common Stock Offering Of Up To $100M

Cryo-Cell International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCEL#NASDAQ">CCEL</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.05) by 180 percent. This is a 50 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $7.929 million which missed the analyst consensus estimate of $8.041 million by 1.39 percent. This is a 1.42 percent decrease over sales of $8.043 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

CCEL

Cryo-Cell International Q2 EPS $0.04 Beats $(0.05) Estimate, Sales $7.929M Miss $8.041M Estimate

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announces its acquisition of the clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. This strategic move strengthens Aptar's support for early-stage drug development by offering formulation, fill and finish services for Phase 1 and 2 clinical trials and enhances adoption of its proprietary devices in early-stage clinical programs.
This acquisition builds on a successful collaboration between Aptar Pharma and Mod3 Pharma, particularly in serving Aptar Pharma customers with Phase 1 and Phase 2 cGMP fill and finish services for orally inhaled nasal drug products (OINDPs), filling a largely unmet need in the market. The capabilities acquired also help Aptar address a growing market demand for agile, high-quality Current Good Manufacturing Practices (cGMP) clinical trial material supply services that complement the segment's existing service offerings. Additionally, the acquisition accelerates the adoption of new drug delivery technologies, initially focusing on OINDPs, with potential expansion into dermal, ophthalmic, injectable and secondary packaging solutions using Aptar's Active Material Science Solutions.
Aptar Pharma will now operate an FDA-inspected, state-of-the-art facility in Boonton, New Jersey. The site includes cGMP cleanrooms, high-potency Active Pharmaceutical Ingredient (API) suites, biologics capabilities, and advanced fill-finish technologies - fully aligned with Aptar Pharma's drug delivery solutions portfolio.
Gael Touya, President of Aptar Pharma, commented, "Our vision at Aptar Pharma is clear: From formulation to patient. By integrating Phase 1 and 2 clinical manufacturing capabilities, we're not just expanding our technical footprint - we're deepening our commitment to customers seeking a seamless and accelerated path to market. This move reinforces our position as a trusted partner from molecule to delivery, and ultimately, to the patient."
Sai Shankar, President, M&amp;A, Strategy, Business Development, Marketing, Drug Services, added, "We're expanding our niche services to help customers move faster in areas of unmet need, and without duplicating the strengths of our trusted partners. This strategic expansion of our services builds on our legacy in drug dosing and dispensing systems by integrating deeper expertise as a drug delivery innovator, as well as product development and formulation, allowing us to offer more specialized and holistic support to our customers."
Dr. Paul Shields, CEO of Mod3 Pharma, remarked, "We are delighted to become part of the Aptar family. This acquisition reflects our shared commitment of accelerating the development of innovative therapies and bringing them to patients faster."

AptarGroup's Aptar Pharma Acquires The Clinical Trial Materials Manufacturing Capabilities Of Mod3 Pharma From SWK Holdings; Terms Not Disclosed

In the last three months, 4 analysts have published ratings on Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Independence Realty Trust, revealing an average target of $22.5, a high estimate of $25.00, and a low estimate of $21.00. Highlighting a 3.56% decrease, the current average has fallen from the previous average price target of $23.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1752613272_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Independence Realty Trust is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Probandt</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Merrill Ross</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Neutral</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Independence Realty Trust. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Independence Realty Trust compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Independence Realty Trust's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Independence Realty Trust's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IRT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Independence Realty Trust analyst ratings.</a>
<h2>Discovering Independence Realty Trust: A Closer Look</h2>
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
<h3>Independence Realty Trust's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Independence Realty Trust displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 0.44%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 5.18%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Independence Realty Trust's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.24% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Independence Realty Trust's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.14%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.65, Independence Realty Trust adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

4 Analysts Have This To Say About Independence Realty Trust

In the last three months, 5 analysts have published ratings on Treehouse Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THS#NYSE">THS</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $23.0, a high estimate of $25.00, and a low estimate of $20.00. A decline of 12.88% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1752613265_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Treehouse Foods by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Lazar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Lazar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Bill Chappell</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Bill Chappell</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matthew Smith</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$24.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Treehouse Foods. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Treehouse Foods compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Treehouse Foods's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Treehouse Foods's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/THS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Treehouse Foods analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Treehouse Foods</h2>
TreeHouse Foods is the largest pure-play private-label manufacturer in the US. Much larger in the past following the 2016 acquisition of Ralcorp, Conagra's former private-label business, the company has since divested several businesses to focus on high-growth categories. At present, the company produces and sells snacks (crackers, pretzels, cookies, and so on), beverages and drink mixes (such as nondairy creamer, coffee, tea, broth), and a select number of grocery products (pickles, refrigerated dough, hot cereal, cheese, and pudding). Its most important sales channel is through retail grocery stores that sell its products under their own brands, with co-manufacturing and food away from home as much smaller channels of distribution for its fare.
<h3>Breaking Down Treehouse Foods's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Treehouse Foods's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -3.5% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Treehouse Foods's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -4.02%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Treehouse Foods's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.07%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Treehouse Foods's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.8%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Treehouse Foods's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.04.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Have This To Say About Treehouse Foods

In the latest quarter, 6 analysts provided ratings for Boston Beer Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $239.17, a high estimate of $279.00, and a low estimate of $187.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 7.89%. 
<img src="https://www.benzinga.com/files/images/story/2025/1752613251_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Boston Beer Co is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Nadine Sarwat</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$230.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Bonnie Herzog</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$187.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$279.00</td>
<td>$279.00</td>
</tr>
<tr>
<td>Sean King</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$279.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Michael Lavery</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Boston Beer Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Boston Beer Co compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Boston Beer Co's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Boston Beer Co's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SAM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Boston Beer Co analyst ratings.</a>
<h2>All You Need to Know About Boston Beer Co</h2>
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.
<h3>Boston Beer Co: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Boston Beer Co showcased positive performance, achieving a revenue growth rate of 6.53% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Boston Beer Co's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.69%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Boston Beer Co's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.96%, the company showcases efficient use of assets and strong financial health.
Debt Management: Boston Beer Co's debt-to-equity ratio is below the industry average. With a ratio of 0.05, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Boston Beer Co Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Analysts' ratings for Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $344.0, a high estimate of $350.00, and a low estimate of $320.00. This current average has decreased by 1.66% from the previous average price target of $349.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1752613243_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Snap-on among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Luke Junk</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$320.00</td>
<td>$349.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Snap-on. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Snap-on compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Snap-on's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Snap-on's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Snap-on analyst ratings.</a>
<h2>About Snap-on</h2>
Snap-on manufactures premium tools and software for repair professionals. Hand tools are sold through a franchisee-operated mobile van network that serve auto technicians who purchase tools at their own expense. A unique element of its business model is that franchisees bear significant risk, as they must invest in the mobile van, inventory, and software. At the same time, franchisees extend personal credit directly to technicians on an individual tool basis. Snap-on currently operates three segments: repair systems and information, commercial and industrial, and tools. Its finance arm provides financing to franchisees to run their operations, which includes offering loans and leases for mobile vans.
<h3>Snap-on: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Snap-on's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -3.48%. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Snap-on's net margin is impressive, surpassing industry averages. With a net margin of 21.08%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Snap-on's ROE stands out, surpassing industry averages. With an impressive ROE of 4.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.01%, the company showcases effective utilization of assets.
Debt Management: Snap-on's debt-to-equity ratio is below the industry average. With a ratio of 0.23, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Snap-on Stock

During the last three months, 10 analysts shared their evaluations of Essex Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $318.7, a high estimate of $355.00, and a low estimate of $293.00. A decline of 1.02% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1752613233_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Essex Property Trust. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$295.00</td>
<td>$297.00</td>
</tr>
<tr>
<td>Buck Horne</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$315.00</td>
<td>-</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$320.00</td>
<td>$344.00</td>
</tr>
<tr>
<td>John Kim</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$317.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$293.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Alexander Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$355.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$344.00</td>
<td>$329.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$328.00</td>
<td>$303.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$309.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$311.00</td>
<td>$315.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Essex Property Trust. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Essex Property Trust compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Essex Property Trust's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Essex Property Trust's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ESS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Essex Property Trust analyst ratings.</a>
<h2>Delving into Essex Property Trust's Background</h2>
Essex Property Trust owns a portfolio of 257 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
<h3>Essex Property Trust's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Essex Property Trust's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 8.82%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 43.72%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Essex Property Trust's ROE excels beyond industry benchmarks, reaching 3.66%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Essex Property Trust's ROA stands out, surpassing industry averages. With an impressive ROA of 1.56%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Essex Property Trust's debt-to-equity ratio is below the industry average at 1.23, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 10 Analyst Projections For Essex Property Trust

In the current market session, First Horizon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) stock price is at $21.22, after a 3.41% drop. However, over the past month, the company's stock spiked by 10.29%, and in the past year, by 29.08%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1752613220_0.png" alt="Past Year Chart" />

<h3>How Does First Horizon P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
First Horizon has a better P/E ratio of 15.26 than the aggregate P/E ratio of 14.04 of the Banks industry. Ideally, one might believe that First Horizon Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1752613220_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: First Horizon

Throughout the last three months, 6 analysts have evaluated Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, and a low estimate of $22.00. This current average has decreased by 0.72% from the previous average price target of $23.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1752613221_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Kenvue among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$24.50</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Anna Lizzul</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$24.50</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kenvue. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kenvue compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Kenvue's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Kenvue's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/KVUE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kenvue analyst ratings.</a>
<h2>Delving into Kenvue's Background</h2>
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson &amp; Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
<h3>Unraveling the Financial Story of Kenvue</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Kenvue's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -3.93%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.
Net Margin: Kenvue's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.27%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Kenvue's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.24%, the company showcases efficient use of assets and strong financial health.
Debt Management: Kenvue's debt-to-equity ratio is below the industry average at 0.88, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KVUE

Assessing Kenvue: Insights From 6 Financial Analysts

Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) has outperformed the market over the past 10 years by 7.01% on an annualized basis producing an average annual return of 18.39%. Currently, Wix.com has a market capitalization of $8.17 billion. 
Buying $100 In WIX: If an investor had bought $100 of WIX stock 10 years ago, it would be worth $543.61 today based on a price of $146.84 for WIX at the time of writing.
<h3>Wix.com's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752613216_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

BNAI

Brand Engagement Network Names Janine Grasso As Interim CEO, Effective Immediately

Health Care

Press Releases

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Financing

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

Comments

CytomX Therapeutics

CytomX Therapeutics (CTMX) Options

CytomX Therapeutics (NASDAQ:CTMX) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL